Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

NEW YORK, Oct. 9, 2012 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:

Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

http://www.reportlinker.com/p0769439/Myasthenia-Gravis-Therapeutics---Pipeline-Assessment-and-Market-Forecasts-to-2019.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Therapy

Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Summary

GlobalData, the industry analysis specialist, has released its new report, "Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Myasthenia Gravis Therapeutics market. The report identifies the key trends shaping and driving the global Myasthenia Gravis Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Myasthenia Gravis Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Myasthenia Gravis Therapeutics market. Its scope includes -

- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Myasthenia Gravis Therapeutics market revenues data from 2006 to 2011, forecast for eight years to 2019.

- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.

- Analysis of the current and future competition in the seven key countries Myasthenia Gravis Therapeutics market.

- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.

- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Myasthenia Gravis Therapeutics market.

- Analysis of key recent licensing and partnership agreements in Myasthenia Gravis Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.

- Develop business strategies by understanding the trends shaping and driving the global Myasthenia Gravis Therapeutics market.

- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Myasthenia Gravis Therapeutics market in future.

- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.

- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.

- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.

- What's the next big thing in the global Myasthenia Gravis Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of Contents

1 Table of Contents 3

1.1 List of Tables 5

1.2 List of Figures 6

2 Myasthenia Gravis Therapeutics - Introduction 7

2.1 Disease Overview 7

2.2 Epidemiology 8

2.3 Etiology and Pathology 10

2.4 Signs and Symptoms 12

2.5 Diagnosis 12

2.5.1 Pharmacological Testing - There are two types of pharmacological tests 12

2.5.2 Serological Testing: 12

2.5.3 Electrophysiological Testing: 13

2.5.4 Imaging Tests: 13

2.6 Treatment and Management Pattern 14

2.6.1 Pharmacological Therapy 14

2.7 Referral Pathway 15

2.8 GlobalData Pipeline Report Guidance 16

3 Myasthenia Gravis Therapeutics - Market Characterization 17

3.1 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Global 17

3.2 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Global 18

3.3 Myasthenia Gravis Therapeutics Market Size (2006-2011) - The US 19

3.4 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - The US 20

3.5 Myasthenia Gravis Therapeutics Market Size (2006-2011) - France 21

3.6 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - France 22

3.7 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Germany 23

3.8 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Germany 24

3.9 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Italy 25

3.10 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Italy 26

3.11 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Spain 27

3.12 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Spain 28

3.13 Myasthenia Gravis Therapeutics Market Size (2006-2011) - The UK 29

3.14 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - The UK 30

3.15 Myasthenia Gravis Therapeutics Market Size (2006-2011) - Japan 31

3.16 Myasthenia Gravis Therapeutics Market Forecast (2011-2019) - Japan 32

3.17 Drivers and Barriers for the Myasthenia Gravis Therapeutics Market 33

3.17.1 Drivers for the Myasthenia Gravis Therapeutics Market 33

3.17.2 Barriers for the Myasthenia Gravis Therapeutics Market 33

3.17.3 Opportunity and Unmet Need Analysis 33

3.18 Key Takeaway 34

4 Myasthenia Gravis Therapeutics - Competitive Assessment 35

4.1 Overview 35

4.2 Strategic Competitor Assessment 35

4.3 Product Profiles of the Major Marketed Products in the Myasthenia Gravis Therapeutics Market 37

4.3.1 Acetylcholinesterase Inhibitor (pyridostigmine) 37

4.3.2 Steroids (prednisone) 38

4.3.3 Immunosuppressants 38

4.3.4 Azathioprine 38

4.3.5 Cyclosporin A 39

4.3.6 Mycophenolate Mofetil (MMF) 39

4.3.7 Venoglobulin-IH 40

4.4 Key Takeaway 40

5 Myasthenia Gravis Therapeutics - Pipeline Assessment 41

5.1 Overview 41

5.2 Strategic Pipeline Assessment 41

5.3 Myasthenia Gravis Therapeutics Pipeline - Pipeline by Phases of Development 41

5.3.1 Myasthenia Gravis Therapeutics - Phase III Pipeline 41

5.3.2 Myasthenia Gravis Therapeutics - Phase II Pipeline 42

5.3.3 Myasthenia Gravis Therapeutics - IND filed Pipeline 42

5.3.4 Technology Trends Analytic Framework 42

5.4 Myasthenia Gravis Therapeutics Market -Pipeline by Mechanism of Action 44

5.5 Myasthenia Gravis Therapeutics - Promising Drugs under Clinical Development 45

5.6 Molecule Profile for Promising Drugs under Clinical Development 45

5.7 Key Takeaway 45

6 Myasthenia Gravis Therapeutics - Clinical Trials Mapping 46

6.1 Clinical Trials by Region/Country (US, EU5 and Japan) 46

6.2 Clinical Trials by Phase 47

6.3 Clinical Trials by Trial Status 48

6.4 Prominent Sponsors 49

6.5 Top Companies Participating in Myasthenia Gravis Therapeutics Clinical Trials 51

7 Strategic Assessment 52

7.1 Key Events Impacting the Future Market 52

7.2 Myasthenia gravis Therapeutics: Implications for Future Market Competition 53

8 Myasthenia Gravis Therapeutics - Future Players 54

8.1 Company Profiles 54

8.2 Cytokinetics, Inc. 54

8.3 Alexion Pharmaceuticals, Inc 55

9 Myasthenia Gravis Therapeutics - Licensing and Partnership Deals 56

10 Myasthenia Gravis Therapeutics - Appendix 57

10.1 Market Definitions 57

10.2 Abbreviations 57

10.3 Methodology 57

10.3.1 Coverage 58

10.3.2 Secondary Research 58

10.3.3 Forecasting 58

10.3.4 Primary Research 60

10.3.5 Expert Panel Validation 61

10.4 Contact Us 61

10.5 Disclaimer 61

10.6 Bibliography 61

List of Tables

Table 1: Clinical Classification of Myasthenia Gravis According to Myasthenia Gravis Foundation of America (MGFA) 7

Table 2: Prevalence of Myasthenia Gravis by Country (G7) 8

Table 3: Myasthenia Gravis Quality of Life Questionnaire 9

Table 4: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2006-2011 17

Table 5: Myasthenia Gravis Therapeutics Market, Global, Forecast ($m), 2011-2019 18

Table 6: Myasthenia Gravis Therapeutics Market, The US, Revenue ($m), 2006-2011 19

Table 7: Myasthenia Gravis Therapeutics Market, The US, Forecasts ($m), 2011-2019 20

Table 8: Myasthenia Gravis Therapeutics Market, France, Revenue ($m), 2006-2011 21

Table 9: Myasthenia Gravis Therapeutics Market, France, Forecasts ($m), 2011-2019 22

Table 10: Myasthenia Gravis Therapeutics Market, Germany, Revenue ($m), 2006-2011 23

Table 11: Myasthenia Gravis Therapeutics Market, Germany, Forecasts ($m), 2011-2019 24

Table 12: Myasthenia Gravis Therapeutics Market, Italy, Revenue ($m), 2006-2011 25

Table 13: Myasthenia Gravis Therapeutics Market, Italy, Forecasts ($m), 2011-2019 26

Table 14: Myasthenia Gravis Therapeutics Market, Spain, Revenue ($m), 2006-2011 27

Table 15: Myasthenia Gravis Therapeutics Market, Spain, Forecasts ($m), 2011-2019 28

Table 16: Myasthenia Gravis Therapeutics Market, The UK, Revenue ($m), 2006-2011 29

Table 17: Myasthenia Gravis Therapeutics Market, The UK, Forecasts ($m), 2011-2019 30

Table 18: Myasthenia Gravis Therapeutics Market, Japan, Revenue ($m), 2006-2011 31

Table 19: Myasthenia Gravis Therapeutics Market, Japan, Forecasts ($m), 2011-2019 32

Table 20: Myasthenia gravis Therapeutics, Phase III Pipeline, 2011 41

Table 21: Myasthenia gravis Therapeutics, Phase II Pipeline, 2011 42

Table 22: Myasthenia Gravis Therapeutics, IND Filed Pipeline, 2011 42

Table 23: Myasthenia Gravis Therapeutics, Clinical Trials by Country, 2011 46

Table 24: Myasthenia Gravis Therapeutics, Clinical Trials by Phase, 2011 47

Table 25: Myasthenia Gravis Therapeutics, Clinical Trials by Status, 2011 48

Table 26: Myasthenia Gravis Therapeutics, Prominent Sponsors, 2011 50

Table 27: Myasthenia Gravis Therapeutics, Top Companies Participating in Therapeutics Clinical Trials, 2011 51

Table 28: Cytokinetics, Inc., Pipeline, 2011 54

Table 29: Alexion Pharmaceuticals, Inc., Pipeline, 2011 55

List of Figures

Figure 1: Normal Neuromuscular Junction 10

Figure 2: Difference Between Normal and Myasthenic Neuromuscular Junctions 11

Figure 3: Signs and Symptoms 12

Figure 4: Repetitive Nerve Stimulation Electrical Tracing 13

Figure 5: Referral Pathway 15

Figure 6: Myasthenia Gravis Therapeutics Market, Global, Revenue ($m), 2006-2011 17

Figure 7: Myasthenia Gravis Therapeutics Market, Global, Forecast ($m), 2011-2019 18

Figure 8: Myasthenia Gravis Therapeutics Market, The US, Forecast ($m), 2006-2011 19

Figure 9: Myasthenia Gravis Therapeutics Market, The US, Forecast ($m), 2011-2019 20

Figure 10: Myasthenia Gravis Therapeutics Market, France, Revenue ($m), 2006-2011 21

Figure 11: Myasthenia Gravis Therapeutics Market, France, Forecast ($m), 2011-2019 22

Figure 12: Myasthenia Gravis Therapeutics Market, Germany, Revenue ($m), 2006-2011 23

Figure 13: Myasthenia Gravis Therapeutics Market, Germany, Forecast ($m), 2011-2019 24

Figure 14: Myasthenia Gravis Therapeutics Market, Italy, Revenue ($m), 2006-2011 25

Figure 15: Myasthenia Gravis Therapeutics Market, Italy, Forecast ($m), 2011-2019 26

Figure 16: Myasthenia Gravis Therapeutics Market, Spain, Revenue ($m), 2006-2011 27

Figure 17: Myasthenia Gravis Therapeutics Market, Spain, Forecast ($m), 2011-2019 28

Figure 18: Myasthenia Gravis Therapeutics Market, The UK, Revenue ($m), 2006-2011 29

Figure 19: Myasthenia Gravis Therapeutics Market, The UK, Forecast ($m), 2011-2019 30

Figure 20: Myasthenia Gravis Therapeutics Market, Japan, Revenue ($m), 2006-2011 31

Figure 21: Myasthenia Gravis Therapeutics Market, Japan, Forecast ($m), 2011-2019 32

Figure 22: Opportunity and Unmet Need in the Myasthenia Gravis Therapeutics Market, 2011 34

Figure 23: Myasthenia Gravis Therapeutics, Strategic Competitor Assessment, 2010 36

Figure 24: Myasthenia gravis Therapeutics - Pipeline by Phase of Development, 2011 41

Figure 25: Myasthenia Gravis Therapeutics, Technology Trends Analytics Framework, 2011 43

Figure 26: Myasthenia Gravis Pipeline, Technology Trends Analytics Framework, Description, 2011 43

Figure 27: Myasthenia Gravis Therapeutics, Pipeline by Mechanism of Action, 2011 44

Figure 28: Myasthenia Gravis Therapeutics, Clinical Trials by Country, 2011 46

Figure 29: Myasthenia Gravis Therapeutics, Clinical Trials by Phase (%), 2011 47

Figure 30: Myasthenia Gravis Therapeutics, Clinical Trials by Status (%), 2011 48

Figure 31: Myasthenia Gravis Therapeutics, Overall Sponsors (%), 2011 49

Figure 32: Myasthenia Gravis Therapeutics, Prominent Sponsors (%), 2011 50

Figure 33: Myasthenia Gravis Therapeutics Market, Drivers and Restraints, 2011 52

Figure 34: Implications for Future Market Competition in the Myasthenia Gravis Therapeutics Market, 2011 53

Figure 35: GlobalData Market Forecasting Model 60

Companies mentioned

Cytokinetics, Inc.

Alexion Pharmaceuticals, Inc

To order this report:

: Myasthenia Gravis Therapeutics - Pipeline Assessment and Market Forecasts to 2019

__________________________

Contact Nicolas: nicolasbombourg@reportlinker.com

US: (805)-652-2626

Intl: +1 805-652-2626

SOURCE Reportlinker



RELATED LINKS
http://www.reportlinker.com

More by this Source

Best of Content We Love 2014 


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

 

PR Newswire Membership

Fill out a PR Newswire membership form or contact us at (888) 776-0942.

Learn about PR Newswire services

Request more information about PR Newswire products and services or call us at (888) 776-0942.